Comprehensive Inpatient Clinical Pharmacy Notes

Clinical Case Reviews & Patient Workups

  • Hypertensive Emergency Patient:

    • Admitted for hypertensive emergency. Home/inpatient blood pressure regimen: hydrochlorothiazide (HCTZ) 12.5 mg12.5\,\text{mg}, amlodipine 10 mg10\,\text{mg}, and valsartan 160 mg160\,\text{mg}.
    • HCTZ was added recently at a low dose of 12.5 mg12.5\,\text{mg}, bringing systolic blood pressure into the target range of 110 to 130 mmHg110\text{ to }130\,\text{mmHg}. Patient previously took HCTZ and reported good tolerance.
    • Heart rate overnight: Sinus bradycardia noted throughout hospital stay, running 50 to 60 bpm50\text{ to }60\,\text{bpm} overnight. Patient is completely asymptomatic (denies lightheadedness, dizziness, blurry vision, headaches, chest pain, or shortness of breath).
    • Physical exam: Patient resting comfortably, warm, well-perfused, equal pulses bilaterally. Abdomen soft, comfortable, non-distended.
    • Scheduled for left heart catheterization due to severe coronary disease; placed NPO overnight with no acute events.
    • Renal ultrasound findings: Symmetric kidney sizes with no evidence of significant renal vascular narrowing.
  • Spine Care & Neurological Pain Patient (Dr. Maroney / Dr. Roy):

    • Medical history: Prior thyroid cancer treated surgically.
    • Comprehensive Spine Care Clinic management: Seen by Dr. Maroney twice, who reported no definitive etiology for upper thoracic spinal pathology; DEXA scan scheduled for October 12.
    • Symptoms and pain radiation: Severe upper thoracic pain radiating into chest, shoulders, neck, face, and left eye (slowed left eye blinking, facial swelling, perioral numbness, partial left-sided tongue numbness). Inability to raise arms above chest level due to extreme thoracic spinal pain.
    • Disease progression: Significant pain and swelling increased over a 4 to 5 day period. Edematous "knobby" lesions initially localized to upper thoracic spine spread down the entire spine within 3 days (evaluated by fellow Dr. Roy).
    • Postural compensation: Sitting relieves direct pressure on the spine compared to supine or side-lying positions; however, torso collapses in a sitting position, forcing upper thoracic spine to compensate, resulting in a visible dorsal hump.
    • Physical exam: Right orbital crackles present; persistent severe cough triggering additional coughing fits. Wheezing noted on auscultation; tracheobronchial involvement evaluated.
    • Vascular workup initiated to evaluate facial/eye edema and upper extremity weakness. Body IR consulted but declined biopsy/procedure due to lack of a safe needle tract.
    • Sedation context: Consuming 45 to 60 g45\text{ to }60\,\text{g} propofol meal intake, remaining consistent during hospital stay.

Anticoagulation Principles, Warfarin Reversal, & Thrombosis Risk

  • Ms. Gupta (Antiphospholipid Syndrome & PE Case Study):

    • Presentation: Admitted with supratherapeutic INR of 3.13.1 and an abdominal hematoma.
    • Warfarin Reversal: Reversed using 4-factor prothrombin complex concentrate (Kcentra) and IV Vitamin K to allow an IR bleeding control procedure. Vitamin K co-administration is necessary alongside Kcentra to promote endogenous factor synthesis as exogenous factors clear.
    • Thrombosis Surge: Patient has underlying Antiphospholipid Syndrome (APS) and extensive PE history. CTA on the 17th showed no new pulmonary emboli; repeat CTA PE on the 20th revealed extensive new PE.
    • Clinical Takeaway: APS patients rapidly form arterial/venous thrombi when anticoagulation is held, even for brief windows (48 hours48\,\text{hours}).
  • Ms. Heard (Retroperitoneal Hematoma & AF Case Study):

    • Admitted through ED with retroperitoneal hematoma while on home warfarin for Atrial Fibrillation (AF). Morning INR 1.91.9.
    • Heart Valve History: History of Transcatheter Aortic Valve Replacement (TAVR) with a bioprosthetic aortic valve.
    • Thromboembolic Risk: Bioprosthetic valves carry significantly lower thrombogenic risk compared to mechanical prosthetic valves, altering the decision-making process for heparin bridging.
  • Pharmacology of Warfarin & Bridging Rationale:

    • Warfarin inhibits Vitamin K epoxide reductase, depleting clotting factors II, VII, IX, and X, as well as anticoagulant Proteins C and S.
    • Half-Lives:
    • Protein C: Short half-life (≈8 hours\approx 8\,\text{hours}), dropping rapidly upon warfarin initiation.
    • Factor VII: Short half-life (≈6 hours\approx 6\,\text{hours}).
    • Factors II and X: Long half-lives (48 to 72 hours48\text{ to }72\,\text{hours}).
    • Hypercoagulable Window: Because anticoagulant Protein C is depleted while procoagulant Factors II and X remain active, starting or restarting warfarin induces a transient hypercoagulable state during the first 2 to 5 days2\text{ to }5\,\text{days}, increasing thrombosis risk.
    • Bridging Requirement: Parenteral anticoagulation (heparin or LMWH) is required for bridging high-risk patients (APS, mechanical valves, recent VTE) until INR achieves therapeutic targets for at least 24 to 48 hours24\text{ to }48\,\text{hours}.
  • Evidence-Based Bridging Guidelines (BRIDGE Trial):

    • The BRIDGE trial investigated periprocedural heparin bridging in patients with Atrial Fibrillation.
    • Findings: No significant reduction in arterial thromboembolism/stroke in bridged vs. non-bridged groups, but a statistically significant increase in major post-operative bleeding in the bridged cohort.
    • Clinical Decision-Making: Bridging is not universally indicated for AF. Risk stratification using the CHA2DS2-VASc\text{CHA}_2\text{DS}_2\text{-VASc} score balances stroke risk against surgical bleeding risk.

Pain Management, Formularies, & Local Anesthetic Systemic Toxicity (LAST)

  • Allergy Re-evaluation & Formulary Constraints:

    • Patients with extensive allergy lists (e.g., 45 to 72 listed allergies) often reflect adverse drug intolerances rather than true IgE-mediated hypersensitivity reactions.
    • Non-opioid allergy lists frequently contain standard agents (e.g., duloxetine marked as causing loss of consciousness; Tylenol marked as causing GI upset).
    • Hospital Formulary Restrictions: Recommending non-formulary medications for chronic pain creates administrative barriers. Hospital pharmacy administration (e.g., Director of Pharmacy Amy Rosenberg) will not approve unconfirmed outpatient drugs for inpatient acute management unless strict criteria are met. Outpatient medications can be used inpatient if brought from home and verified, provided they are non-controlled.
  • Adjuvant Pharmacotherapy for Chronic Pain:

    • Ketamine: Nondelirium/nonopioid agent indicated for refractory acute/chronic pain or severe opioid tolerance (e.g., sickle cell vaso-occlusive crises). Adverse effects include euphoria, hallucinations, and out-of-body experiences.
    • Buspirone (Buspar): Anxiolytic utilized when chronic pain is exacerbated by comorbid anxiety.
    • Hydroxyzine (Vistaril): Sedating anxiolytic effective for nocturnal pain exacerbations and insomnia.
  • Local Anesthetic Systemic Toxicity (LAST):

    • Etiology: Systemic absorption of local anesthetics (e.g., lidocaine, bupivacaine) following regional nerve blocks (e.g., sciatic block) or local infiltration, even without direct intravascular injection.
    • Clinical Presentation: Initial signs include perioral numbness, tongue paresthesia, lightheadedness, metallic taste, progressing to muscular twitching, tonic-clonic seizures, CNS depression, coma, and cardiovascular collapse/arrhythmias.
    • Dosing Safety: Dosing must be calculated using actual body weight if actual body weight is less than ideal body weight (ABW<IBW\text{ABW} < \text{IBW}) to prevent accidental overdosing in frail patients.
    • Maximum Allowed Doses: Epinephrine co-administration causes local vasoconstriction, reducing systemic absorption rate and increasing maximum weight-based dosage thresholds (e.g., lidocaine plain vs. lidocaine with epinephrine).
    • Antidote/Reversal Protocol: Intravenous 20%20\% Lipid Emulsion (Intralipid) therapy acts as a lipid sink to sequester local anesthetics from plasma and tissues.

Inpatient Glycemic Management & Insulin Dosing Regimens

  • Inpatient Glycemic Targets:

    • Recommended blood glucose target for non-critically ill hospitalized patients: 140 to 180 mg/dL140\text{ to }180\,\text{mg/dL}.
  • Basal-Bolus vs. Sliding Scale Insulin:

    • Standalone Sliding Scale Insulin (SSI) is strongly discouraged by clinical guidelines as it represents reactive care ("chasing hyperglycemia").
    • Basal-Bolus Regimen: Preferred method consisting of basal insulin (e.g., glargine/Lantus), scheduled prandial insulin (e.g., aspart/NovoLog), and correctional sliding scale insulin.
  • Insulin Dosing Calculations:

    • Total Daily Dose (TDD) initial estimation: 0.4 units/kg/day0.4\,\text{units/kg/day} for insulin-naive Type 2 Diabetics with normal renal function, or 80%80\% of total home insulin dose.
    • TDD Allocation: 50%50\% allocated to basal insulin once daily; 50%50\% divided equally across three mealtime prandial boluses (≈16.6%\approx 16.6\% per meal).
  • Dietary Considerations:

    • Carbohydrate Consistent Diet: Provides predictable carbohydrate loads (45 to 60 g45\text{ to }60\,\text{g} per meal), facilitating fixed prandial insulin dosing.
  • Type 1 vs. Type 2 Sensitivity Differences:

    • Type 1 Diabetes: Complete endogenous insulin deficiency with intact insulin sensitivity. Small fixed prandial doses (e.g., 3 units3\,\text{units}) can induce severe hypoglycemia (BG<60–70 mg/dL\text{BG} < 60\text{--}70\,\text{mg/dL}) if meal intake is low.
    • Type 2 Diabetes: High insulin resistance. Equivalent doses yield minimal blood glucose drops.
  • Overbasalization Risk:

    • Basal insulin doses should not exceed 0.5 units/kg/day0.5\,\text{units/kg/day}. Titrating basal insulin upward to cover mealtime glucose spikes leads to overbasalization, predisposing patients to nocturnal hypoglycemia (BG<50 mg/dL\text{BG} < 50\,\text{mg/dL}). If basal dose exceeds 0.5 units/kg/day0.5\,\text{units/kg/day}, cap the basal dose and titrate prandial insulin instead.
  • Outside Snacks:

    • For uncooperative patients consuming personal outside food (e.g., Chick-fil-A, milkshakes), order PRN prandial insulin for snacks rather than leaving hyperglycemia unaddressed.

Diabetic Ketoacidosis (DKA) Principles, Diagnosis, & Protocols

  • Diagnostic Criteria for DKA:

    1. Hyperglycemia: Blood Glucose >250 mg/dL> 250\,\text{mg/dL}.
    2. Ketoacidosis: Positive serum/urine ketones, or serum beta-hydroxybutyrate (BHB)≥3.0 mmol/L\text{beta-hydroxybutyrate (BHB)} \ge 3.0\,\text{mmol/L}.
    3. Metabolic Acidosis: Venous/arterial pH<7.30\text{pH} < 7.30 and serum bicarbonate HCO3−<18 mEq/L\text{HCO}_3^- < 18\,\text{mEq/L}.
  • Pathophysiology:

    • Absolute insulin deficiency halts cellular glucose uptake, forcing a shift to lipolysis and muscle catabolism. Anaerobic fatty acid oxidation yields acetoacetate and beta-hydroxybutyrate, inducing high anion gap metabolic acidosis.
  • Cornerstones of Management:

    1. Fluid Resuscitation: Isotonic IV fluids (0.9% NaCl0.9\%\,\text{NaCl} or Lactated Ringer's) to restore intravascular volume and renal perfusion. Use caution in ESRD patients to prevent fluid overload.
    2. Continuous Insulin Infusion: Regular insulin IV drip to stop lipolysis, clear ketonemia, and close the anion gap.
    3. Electrolyte/Potassium Monitoring:
    • Insulin drives potassium into cells, causing rapid serum hypokalemia.
    • Check potassium every 2 to 4 hours2\text{ to }4\,\text{hours}.
    • Ensure K+>3.3 mEq/LK^+ > 3.3\,\text{mEq/L} prior to starting insulin. Add 20 to 30 mEq/L20\text{ to }30\,\text{mEq/L} KCl to IV fluids once K+<5.2 mEq/LK^+ < 5.2\,\text{mEq/L}.
  • Fluid Adjustment During DKA Resolution:

    • When blood glucose drops below 250 mg/dL250\,\text{mg/dL} while metabolic acidosis/ketonemia persists, add 5% or 10%5\%\text{ or }10\% Dextrose (e.g., D5W\text{D}_5\text{W} or D512NS\text{D}_5\frac{1}{2}\text{NS} with KCl\text{KCl}) to IV fluids to allow continued insulin infusion without causing hypoglycemia.
  • DKA Resolution Criteria:

    • Blood glucose <200–250 mg/dL< 200\text{--}250\,\text{mg/dL}, serum bicarbonate ≥15–18 mEq/L\ge 15\text{--}18\,\text{mEq/L}, venous pH>7.30\text{pH} > 7.30, and normalized anion gap (≤12 mEq/L\le 12\,\text{mEq/L}).
  • Euglycemic DKA:

    • Occurs in patients taking SGLT2 inhibitors; presents with metabolic ketoacidosis despite blood glucose levels <250 mg/dL< 250\,\text{mg/dL}.

Chronic Kidney Disease (CKD/ESRD) & Anemia Management

  • Ms. Kayla Steward Case:

    • 32-year-old female with T1D, ESRD on hemodialysis, gastroparesis, and chronic ankle hardware infection.
    • Admitted with severe DKA (initial BHB=9.0 mmol/L\text{BHB} = 9.0\,\text{mmol/L}, pH=7.20\text{pH} = 7.20, BG≈500 mg/dL\text{BG} \approx 500\,\text{mg/dL}). Ankle surgery postponed. Persistent sinus tachycardia (HR>100 bpm\text{HR} > 100\,\text{bpm}) signals potential underlying sepsis triggering DKA.
  • KDIGO Guidelines for Anemia in CKD/ESRD:

    • Anemia Cutoff: Hemoglobin <12.0 g/dL< 12.0\,\text{g/dL} (females) or <13.0 g/dL< 13.0\,\text{g/dL} (males).
    • ESA Initiation Threshold: KDIGO guidelines recommend starting Erythropoiesis-Stimulating Agents (ESAs) when hemoglobin is <10.5 g/dL< 10.5\,\text{g/dL}. Primary target is symptom reduction and avoiding red blood cell transfusions (transfusion threshold <7.0 g/dL< 7.0\,\text{g/dL}).
  • Comparison of ESA Options:

    • Darbepoetin alfa (Aranesp): Weekly dosing, supplied in pre-filled syringes, eliminates compounding costs in hospital IV rooms. Preferred inpatient agent.
    • Epoetin alfa (Epogen/Procrit): Dosed 3 times weekly, requires compounding. Retained on formulary for Jehovah's Witness patients or patients refusing blood products due to stronger clinical trial evidence in those subpopulations.
  • ESA Safety & Dosing Thresholds:

    • Initiation: Start when Hb<10.5 g/dL\text{Hb} < 10.5\,\text{g/dL}.
    • Upper Target / Hold Threshold: Hold or decrease dose if Hb>11.5 g/dL\text{Hb} > 11.5\,\text{g/dL} due to risk of hypertension, stroke, seizures, and thromboembolism.
    • Onset of Action: Bone marrow erythropoiesis takes 1 to 2 weeks1\text{ to }2\,\text{weeks} to demonstrate hemoglobin elevation.
    • Monitoring Rate of Rise: Hemoglobin increase >1.5 g/dL> 1.5\,\text{g/dL} within a 2-week2\text{-week} period is excessively rapid and requires dose reduction or hold to mitigate cardiovascular toxicity.

Clinical Rotation Logistics & Educational Guidelines

  • Patient Workup Load:

    • Students/interns are required to maintain a daily census of 3 patients.
    • When selecting new patients, students may pick up two highly complex patients or three moderate patients.
  • Topic Discussion Expectations:

    • Rotation topic discussions focus on clinical reasoning, rationale, and guideline application (e.g., IDSA/ATS guidelines for pneumonia, short-course antibiotic therapy, COPD exacerbations).
    • Discussions are non-graded/no right-or-wrong answer environments designed to articulate treatment choices.
  • Documentation & Printing:

    • Log into desktop workstations, select patient list, right-click, select print list, and send to Copy Room 3318 or nursing station printers.
  • Reflective Feedback:

    • Weekly 15-to-30-minute self-reflections submitted on Google Classroom every Friday.